UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Annals of oncology, 2020-06, Vol.31 (6), p.674-696

2020

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

The New England journal of medicine, 2021-06, Vol.384 (25), p.2394-2405

2021

Link zum Volltext

Verfügbarkeit prüfen

Research needs in breast cancer

Annals of oncology, 2017-02, Vol.28 (2), p.208-217

2017

Link zum Volltext

Verfügbarkeit prüfen

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of oncology, 2022-12, Vol.33 (12), p.1250-1268

2022

Link zum Volltext

Verfügbarkeit prüfen

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2716-2725

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-08-03: Looking forward to the TNM 9th edition: Is it time to stage the different breast cancer subtypes as distinct diseases?

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-03

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-08-01: Is the 8th edition of the breast cancer TNM staging system an improvement over the 7th edition?

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-01

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-08-27: The 21-gene Recurrence® (RS) Score assay in estrogen receptor positive node negative breast cancer: Real-world chemotherapy usage and patient characteristics within the intermediate and high-risk RS category

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-27

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-08-13: Exploring the role of ctDNA in triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-08-13

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Journal of clinical oncology, 2023-11, Vol.41 (33), p.5118

2023

Link zum Volltext

Verfügbarkeit prüfen

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

Annals of oncology, 2007-01, Vol.18 (1), p.45-51

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-13-02: Real world outcomes of adjuvant FECD, ddACT and ACT for the treatment of early stage breast cancer - A multicenter retrospective analysis

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-13-02

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-19-01

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-03

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-25

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD3-10-PD3-10

2019

Link zum Volltext

Verfügbarkeit prüfen

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival

Cancer research (Chicago, Ill.), 2006, Vol.66 (1), p.393-403

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-12-10: Comparison of the efficacy of tamoxifen and aromatase inhibitors on survival in adjuvant menopausal breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-12-10

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-12-05: The BC provincial experience on FEC-D vs. AC-taxane protocol as adjuvant treatment for breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P3-P3-12-05

2013

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression

Cancer research (Chicago, Ill.), 2004-08, Vol.64 (15), p.5068-5073

2004

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.478-484

1999

Link zum Volltext

Verfügbarkeit prüfen

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment:Challenges for Drug Development?

JNCI : Journal of the National Cancer Institute, 1999-08, Vol.91 (15), p.1281-1287

1999

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-07-06

2017

Link zum Volltext

Verfügbarkeit prüfen

MDM2 protein expression is a negative prognostic marker in breast carcinoma

Modern pathology, 2006-01, Vol.19 (1), p.69-74

2006

Link zum Volltext

Verfügbarkeit prüfen

Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories

Clinical breast cancer, 2004, Vol.5 (1), p.52-58

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Research needs in breast cancer

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Abstract P4-08-03: Looking forward to the TNM 9th edition: Is it time to stage the different breast cancer subtypes as distinct diseases?

Abstract P4-08-01: Is the 8th edition of the breast cancer TNM staging system an improvement over the 7th edition?

Abstract P4-08-27: The 21-gene Recurrence® (RS) Score assay in estrogen receptor positive node negative breast cancer: Real-world chemotherapy usage and patient characteristics within the intermediate and high-risk RS category

Abstract P3-08-13: Exploring the role of ctDNA in triple negative breast cancer

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

Abstract P1-13-02: Real world outcomes of adjuvant FECD, ddACT and ACT for the treatment of early stage breast cancer - A multicenter retrospective analysis

Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer

Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups

Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2

Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival

Abstract P5-12-10: Comparison of the efficacy of tamoxifen and aromatase inhibitors on survival in adjuvant menopausal breast cancer

Abstract P3-12-05: The BC provincial experience on FEC-D vs. AC-taxane protocol as adjuvant treatment for breast cancer

Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment:Challenges for Drug Development?

Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

MDM2 protein expression is a negative prognostic marker in breast carcinoma

Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories

Suchergebnisse filtern